Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback